Welcome to our dedicated page for Kaya Hldgs news (Ticker: KAYS), a resource for investors and traders seeking the latest updates and insights on Kaya Hldgs stock.
Kaya Holdings, Inc. (OTCQB: KAYS) generates news across several emerging sectors, including psilocybin treatment services, medical and recreational cannabis, and, more recently, digital assets and cryptocurrency. Its announcements provide insight into how the company is developing The Sacred Mushroom™ psilocybin treatment center in Portland, Oregon, managing cannabis-related brands and licenses, and pursuing a Digital Assets Treasury (DAT) strategy through a planned cryptocurrency subsidiary.
News items for KAYS often highlight regulatory milestones and operational updates at The Sacred Mushroom, such as the award of a psilocybin service center license from the Oregon Health Authority, the start of appointment scheduling, the grand opening of the facility, and the introduction of programs like the "Synergy by Design" journey customization framework. Releases also cover educational initiatives, including e-books on psilocybin and commentary on topics such as the potential use of psilocybin in mental health applications.
On the corporate side, Kaya Holdings’ news includes engagements with advisory firms like Greentree Financial Group and Conduit Advisors to support the development of a cryptocurrency operating subsidiary and implementation of its digital assets treasury strategy. Related updates may describe planned joint ventures with cryptocurrency foundations and steps the company is taking to restructure its balance sheet in connection with this strategy.
Investors and observers following KAYS news can expect coverage of licensing developments, facility launches, program rollouts at The Sacred Mushroom, cannabis licensing and branding updates, and strategic moves in digital assets. The news feed provides a way to track how the company’s psilocybin, cannabis and cryptocurrency initiatives evolve under the regulatory and market conditions it describes in its public statements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kaya Holdings, Inc. (KAYS) reported a new partnership with Total Holistic Center to develop a ketamine treatment model. This collaboration marks a significant step toward launching Fifth Dimension Therapeutics Mind Care Clinics and Telehealth Services across Florida. The clinics will initially operate from Total Holistic’s existing locations in Boca Raton, Fort Worth, and Miami Beach, under the direction of Dr. Anya Temer. The treatment aims to address treatment-resistant depression and PTSD. Kaya plans to shift its focus towards domestic psychedelic solutions as it expands its cannabis operations internationally.
Kaya Holdings, Inc. (OTCQB:KAYS) has launched Fifth Dimension Therapeutics (FDT) to provide psychedelic treatments targeting mental health disorders like PTSD and addiction. Bryan Arnold, a senior employee, is pursuing a Psilocybin Facilitator License in Oregon, expected to complete by April. Attorney Glenn E.J. Murphy joins FDT's Board, enhancing connections with pharmaceutical firms and aiding in developing intellectual property and joint ventures. Mental health disorders impose significant economic burdens, with projected costs reaching $6 trillion by 2030. The U.S. psychedelics market is estimated at $2.8 billion, forecasted to reach $8.9 billion by 2029.
Kaya Holdings, Inc. (KAYS) announced plans to obtain licenses for psilocybin manufacturing and facilitation service centers in Oregon, anticipating strong market demand as the global psychedelic therapeutics sector could reach $8-10 billion by 2028. The Oregon Health Authority is expected to start issuing licenses in January 2023. The company, first to operate cannabis licenses across all categories in the U.S., sees this move as a natural extension of its operations. Psilocybin shows promise in treating mental disorders, with market estimates projecting significant growth.
Kaya Holdings (OTCQB: KAYS) announced that its subsidiary, Kaya Farms Greece, received a Cannabis Installation License for its Greek Kaya project in Epidaurus, Greece. This facility will produce KAYS proprietary cannabis brands for EU markets. The project includes 25,000 sq ft for cultivation, a 15,000 sq ft extraction facility, and a 10,000 sq ft packing area, with expansion potential. Management is negotiating a property purchase agreement and highlights the strategic importance of the license for operations in growing cannabis markets in Europe.
Kaya Holdings (OTCQB:KAYS) announced the acquisition of a 50% stake in the Greek Kaya Project, a medical cannabis facility in Epidaurus, Greece, enhancing its footprint in the EU market.
The project features 50,000 square feet of space, including 25,000 square feet for cultivation, a 15,000 square foot EU-GMP extraction facility, and a 10,000 square foot packing area. The facility aims to fast-track KAYS' cannabis products for distribution in various EU markets, awaiting final licensing and project financing.
Kaya Holdings, Inc. (KAYS) has successfully sold its cannabis facility in Eugene, Oregon for $1.325 million. The proceeds will be used to repay debts and bolster the company's balance sheet, enabling further global expansion activities, particularly in Greece and Israel. The planned facilities aim to produce 600,000 pounds of premium cannabis annually for export. This sale will increase cash reserves by approximately $0.09 per share without issuing new shares, decreasing outstanding shares by 6.5%. KAYS remains focused on building a competitive position in the cannabis industry.